Literature DB >> 11520757

Steroid management in giant cell arteritis.

C C Chan1, M Paine, J O'Day.   

Abstract

AIM: Ocular involvement in giant cell arteritis (GCA) is an ophthalmic emergency which, if untreated, can progress to permanent blindness. There is little evidence in the literature to support current protocols for the acute treatment of GCA with steroids. The authors sought to review the effects of intravenous and oral steroids in GCA.
METHODS: This retrospective study reviewed the records of 100 consecutive patients with biopsy proved giant cell arteritis. 73 patients with visual loss who were treated at the Royal Victorian Eye and Ear Hospital (RVEEH) and St Vincent's Hospital were included in the final series. The authors studied the management of the patients in the first week after presentation, analysing types of treatment, dose, effect on visual acuity, and complications.
RESULTS: All the patients except one had visual loss due to anterior ischaemic optic neuropathy (AION). 17 patients (23%) had bilateral eye involvement. Visual acuity improved in 21 of 73 patients (29%) by a mean of two Snellen chart lines after commencement of steroids. There was an increased likelihood of improved vision in the group who had intravenous steroids (40%) compared with those who received oral steroids (13%). In all except four patients (95%) vision remained stable at 1 month review.
CONCLUSIONS: Prompt treatment of GCA with steroids leads to improvement of visual acuity in a significant number of cases. Intravenous steroids may offer a greater prospect of improvement compared with oral steroids. A prospective trial comparing intravenous with oral steroids is needed to validate these findings and would not expose elderly patients to unacceptable risks.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11520757      PMCID: PMC1724128          DOI: 10.1136/bjo.85.9.1061

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  24 in total

1.  TEMPORAL ARTERITIS.

Authors:  A G WHITFIELD; M BATEMAN; W T COOKE
Journal:  Br J Ophthalmol       Date:  1963-09       Impact factor: 4.638

2.  OCCULT TEMPORAL ARTERITIS.

Authors:  J F CULLEN
Journal:  Trans Ophthalmol Soc U K       Date:  1963

3.  Ocular manifestations of giant cell arteritis.

Authors:  S S Hayreh; P A Podhajsky; B Zimmerman
Journal:  Am J Ophthalmol       Date:  1998-04       Impact factor: 5.258

Review 4.  Giant cell (temporal) arteritis.

Authors:  G G Hunder
Journal:  Rheum Dis Clin North Am       Date:  1990-05       Impact factor: 2.670

5.  Bilateral ocular ischemic syndrome secondary to giant cell arteritis progressing despite corticosteroid treatment.

Authors:  J M Hwang; C A Girkin; J D Perry; J C Lai; N R Miller; D B Hellmann
Journal:  Am J Ophthalmol       Date:  1999-01       Impact factor: 5.258

6.  Anterior ischaemic optic neuropathy. Differentiation of arteritic from non-arteritic type and its management.

Authors:  S S Hayreh
Journal:  Eye (Lond)       Date:  1990       Impact factor: 3.775

Review 7.  Giant cell arteritis: difficult decisions in diagnosis, investigation and treatment.

Authors:  E W Paice
Journal:  Postgrad Med J       Date:  1989-10       Impact factor: 2.401

8.  The epidemiology of giant cell arteritis including temporal arteritis and polymyalgia rheumatica. Incidences of different clinical presentations and eye complications.

Authors:  B A Bengtsson; B E Malmvall
Journal:  Arthritis Rheum       Date:  1981-07

9.  Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment.

Authors:  M A González-Gay; R Blanco; V Rodríguez-Valverde; V M Martínez-Taboada; M Delgado-Rodriguez; M Figueroa; E Uriarte
Journal:  Arthritis Rheum       Date:  1998-08

10.  Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin.

Authors:  K T Calamia; G G Hunder
Journal:  Arthritis Rheum       Date:  1981-11
View more
  20 in total

Review 1.  [Therapy of primary systemic vasculitis].

Authors:  K de Groot; W L Gross; B Hellmich
Journal:  Internist (Berl)       Date:  2003-12       Impact factor: 0.743

2.  Heparin therapy in giant cell arteritis.

Authors:  L M Buono; R Foroozan; M de Virgiliis; P J Savino
Journal:  Br J Ophthalmol       Date:  2004-02       Impact factor: 4.638

Review 3.  Giant cell arteritis.

Authors:  J M Calvo-Romero
Journal:  Postgrad Med J       Date:  2003-09       Impact factor: 2.401

Review 4.  Aortitis.

Authors:  Heather L Gornik; Mark A Creager
Journal:  Circulation       Date:  2008-06-10       Impact factor: 29.690

Review 5.  The treatment of giant cell arteritis.

Authors:  J Alexander Fraser; Cornelia M Weyand; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2008

Review 6.  Giant cell arteritis: Current treatment and management.

Authors:  Cristina Ponte; Ana Filipa Rodrigues; Lorraine O'Neill; Raashid Ahmed Luqmani
Journal:  World J Clin Cases       Date:  2015-06-16       Impact factor: 1.337

Review 7.  The Treatment of Giant Cell Arteritis.

Authors:  Imran Jivraj; Madhura Tamhankar
Journal:  Curr Treat Options Neurol       Date:  2017-01       Impact factor: 3.598

8.  Giant Cell Arteritis.

Authors:  Jennifer K. Hall; Laura J. Balcer
Journal:  Curr Treat Options Neurol       Date:  2004-01       Impact factor: 3.598

9.  Current diagnosis and treatment of temporal arteritis.

Authors:  Wolfgang A Schmidt
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-04

Review 10.  Neuro-ophthalmic complications in giant cell arteritis.

Authors:  Frances A Borg; Victoria L J Salter; Bhaskar Dasgupta
Journal:  Curr Allergy Asthma Rep       Date:  2008-07       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.